<DOC>
	<DOCNO>NCT01266135</DOCNO>
	<brief_summary>This study design evaluate safety , tolerability , pharmacokinetics efficacy QAX576 patient idiopathic pulmonary fibrosis .</brief_summary>
	<brief_title>Safety Efficacy QAX576 Patients With Idiopathic Pulmonary Fibrosis ( IPF )</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<criteria>Inclusion criterion Diagnosis Idiopathic Pulmonary Fibrosis ( IPF ) , base appropriate clinical definition IPF detail ATS/ERS/JRS/ALAT Statement : Idiopathic Pulmonary Fibrosis : Evidencebased Guidelines Diagnosis Management Diagnosis must confirm diagnostic HRCT surgical lung biopsy . A 6minute walk test ( 6MWT ) distance â‰¥50 meter Screening ( use supplemental oxygen allow ) . Exclusion criterion Smokers ( use tobacco product previous 3 month ) . Urine cotinine level measure screening subject . Smokers define subject report tobacco use urine cotinine level range define 'smokers ' per local lab . Lung residual volume &gt; 120 % predict Screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Interstitial Lung Disease</keyword>
	<keyword>Usual Interstitial Pneumonia</keyword>
	<keyword>Fibrosis ,</keyword>
	<keyword>Pulmonary Fibrosis ,</keyword>
	<keyword>Respiratory Disease ,</keyword>
	<keyword>Interstitial Lung Disease ,</keyword>
	<keyword>Biological Therapy ,</keyword>
	<keyword>Therapeutic Uses ,</keyword>
</DOC>